Grünenthal announced the acquisition of the American pharmaceutical manufacturer Valinor Pharma for $250 million in order to obtain the rights to Movantik (naloxegol).

Allyx Therapeutics has begun a new clinical trial for its key drug, ALX-001, administering it to the first patient to assess safety, pharmacokinetics, and potential therapeutic effects in Parkinson’s disease.

Zealand Pharma and Boehringer Ingelheim (BI) announced breakthrough clinical trial results for Survodutide, a novel drug targeting metabolic dysfunction-associated steatohepatitis (MASH).

Merck and EyeBio Announce Start of Phase 2b/3 Clinical Study for Restoret™ to Treat Diabetic Macular Edema.

September 5, the NMPA Center for Drug Evaluation (CDE) announced that the clinical trial application (IND) for SKB571, an injectable drug from Kelun-Biotech, has been accepted.

BlueRock Therapeutics has obtained FDA approval for their IND application for OpCT-001, a cell therapy derived from iPSCs, targeting primary photoreceptor diseases.

Sep 6th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Vasa Therapeutics Begins Phase 1 Human Trial of VS-041 for Treating Heart Failure with Preserved Ejection Fraction.

GC Biopharma revealed that its joint effort with Hanmi Pharmaceutical on the Fabry treatment 'LA-GLA' (GC1134A/HM15421) has been granted IND approval by the U.S. FDA to initiate a Phase 1/2 clinical study.

REGENXBIO Inc. revealed encouraging findings from the Phase I/II/III CAMPSIITE® study of RGX-121, aimed at treating Mucopolysaccharidosis Type II (MPS II).

Evommune has announced the initiation of a Phase 2 trial for EVO756, with the first patient now enrolled.

LENZ Therapeutics, a biopharmaceutical company dedicated to developing the first and only eye drop based on aceclidine (LNZ100) to improve near vision in presbyopia patients.